Study wrapper · #143
Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis.
Editor's note
A systematic review and meta-analysis of 11 randomized trials (12 comparisons; 25,067 participants) of semaglutide versus placebo or active control. Researchers reported a 32% reduction in major adverse cardiovascular events (pooled OR 0.68; 95% CI 0.52 to 0.91), with the estimate stable after removing the STEP obesity or heart-failure trials, and low heterogeneity, consistent with semaglutide's dedicated cardiovascular outcome trials. Importantly, the analysis balances this against harms: higher risk of any GI disorder (RR 1.47), gallbladder events (RR 2.37), and discontinuation for GI intolerance (RR 2.32). Caveats the authors stress: seven of 11 trials were >=75% White with no low-income-country sites, limiting generalizability, and cost-utility estimates ($180,000 to 260,000/QALY) sit above usual willingness-to-pay thresholds. Weight this as solid randomized evidence of cardiovascular risk reduction, tempered by real GI and gallbladder trade-offs, representativeness limits, and cost questions, not an unqualified benefit.
Plain-language abstract
This analysis combined 11 randomized trials, covering just over 25,000 people, that compared semaglutide with a placebo or another treatment. Pooling the results, semaglutide was linked to a 32% lower risk of major heart problems such as heart attack, stroke, or cardiovascular death. This held up even when the researchers removed the obesity-focused or heart-failure trials, and the trials agreed closely with each other. The benefit appeared larger in people with lower body weight and cholesterol. On the safety side, semaglutide was linked to more digestive problems (about 47% higher risk), more gallbladder problems (more than double the risk), and more people stopping the drug because of stomach upset. The authors caution that most trials enrolled mainly White participants from higher-income countries, limiting how broadly the results apply, and that the drug's cost per unit of health benefit is high by usual standards. They call for more diverse, global trials.